RT Journal Article
A1 Xiao, Yifan
A1 Meng, Jiahao
A1 Gao, Shuguang
T1 Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
JF JAMA
JO JAMA
YR 2024
DO 10.1001/jama.2024.2600
SN 0098-7484
AB To the Editor As reported by Dr Aronne and colleagues, tirzepatide demonstrates therapeutic benefits in weight loss; adults with obesity completing the 36-week lead-in period of the trial experienced a mean weight reduction of 20.9%. From randomization at week 36, those who switched to receiving placebo had a 14% weight regain, while those continuing tirzepatide achieved an additional 5.5% weight reduction during the 52-week double-blind period. However, we have several concerns.First, questions persist regarding the safety of tirzepatide, such as a possible increased risk of thyroid cancer. Although a 20.9% weight reduction was observed after 36 weeks of tirzepatide use, cessation led to significant weight regain. This result may prompt patients to continue using the drug to maintain weight loss. However, tirzepatide has been associated with an elevated risk of thyroid cancer, influenced by the duration of exposure.
RD 5/20/2024
UL https://doi.org/10.1001/jama.2024.2600